225 related articles for article (PubMed ID: 19171484)
1. 1-Amido-1-phenyl-3-piperidinylbutanes - CCR5 antagonists for the treatment of HIV. Part 1.
Barber CG; Blakemore DC; Chiva JY; Eastwood RL; Middleton DS; Paradowski KA
Bioorg Med Chem Lett; 2009 Feb; 19(4):1075-9. PubMed ID: 19171484
[TBL] [Abstract][Full Text] [Related]
2. 1-Amido-1-phenyl-3-piperidinylbutanes--CCR5 antagonists for the treatment of HIV: part 2.
Barber CG; Blakemore DC; Chiva JY; Eastwood RL; Middleton DS; Paradowski KA
Bioorg Med Chem Lett; 2009 Mar; 19(5):1499-503. PubMed ID: 19185490
[TBL] [Abstract][Full Text] [Related]
3. The discovery of tropane-derived CCR5 receptor antagonists.
Armour DR; de Groot MJ; Price DA; Stammen BL; Wood A; Perros M; Burt C
Chem Biol Drug Des; 2006 Apr; 67(4):305-8. PubMed ID: 16629828
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of CCR5 antagonists containing modified 4-piperidinyl-2-phenyl-1-(phenylsulfonylamino)-butane.
Shah SK; Chen N; Guthikonda RN; Mills SG; Malkowitz L; Springer MS; Gould SL; Demartino JA; Carella A; Carver G; Holmes K; Schleif WA; Danzeisen R; Hazuda D; Kessler J; Lineberger J; Miller M; Emini EA; MacCoss M
Bioorg Med Chem Lett; 2005 Feb; 15(4):977-82. PubMed ID: 15686896
[TBL] [Abstract][Full Text] [Related]
5. Anti-HIV-1 entry optimization of novel imidazopiperidine-tropane CCR5 antagonists.
Ernst J; Dahl R; Lum C; Sebo L; Urban J; Miller SG; Lundström J
Bioorg Med Chem Lett; 2008 Feb; 18(4):1498-501. PubMed ID: 18194864
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity.
Imamura S; Ichikawa T; Nishikawa Y; Kanzaki N; Takashima K; Niwa S; Iizawa Y; Baba M; Sugihara Y
J Med Chem; 2006 May; 49(9):2784-93. PubMed ID: 16640339
[TBL] [Abstract][Full Text] [Related]
7. Novel 4,4-disubstituted piperidine-based C-C chemokine receptor-5 inhibitors with high potency against human immunodeficiency virus-1 and an improved human ether-a-go-go related gene (hERG) profile.
Kazmierski WM; Anderson DL; Aquino C; Chauder BA; Duan M; Ferris R; Kenakin T; Koble CS; Lang DG; McIntyre MS; Peckham J; Watson C; Wheelan P; Spaltenstein A; Wire MB; Svolto A; Youngman M
J Med Chem; 2011 Jun; 54(11):3756-67. PubMed ID: 21539377
[TBL] [Abstract][Full Text] [Related]
8. CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological evaluation of piperidine-4-carboxamide derivatives.
Imamura S; Nishikawa Y; Ichikawa T; Hattori T; Matsushita Y; Hashiguchi S; Kanzaki N; Iizawa Y; Baba M; Sugihara Y
Bioorg Med Chem; 2005 Jan; 13(2):397-416. PubMed ID: 15598561
[TBL] [Abstract][Full Text] [Related]
9. Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc.
Price DA; Armour D; de Groot M; Leishman D; Napier C; Perros M; Stammen BL; Wood A
Bioorg Med Chem Lett; 2006 Sep; 16(17):4633-7. PubMed ID: 16782336
[TBL] [Abstract][Full Text] [Related]
10. [2-(4-Phenyl-4-piperidinyl)ethyl]amine based CCR5 antagonists: derivatizations at the N-terminal of the piperidine ring.
Duan M; Aquino C; Ferris R; Kazmierski WM; Kenakin T; Koble C; Wheelan P; Watson C; Youngman M
Bioorg Med Chem Lett; 2009 Mar; 19(6):1610-3. PubMed ID: 19233649
[TBL] [Abstract][Full Text] [Related]
11. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 3: SAR studies on the benzylpyrazole segment.
Shu M; Loebach JL; Parker KA; Mills SG; Chapman KT; Shen DM; Malkowitz L; Springer MS; Gould SL; DeMartino JA; Siciliano SJ; Salvo JD; Lyons K; Pivnichny JV; Kwei GY; Carella A; Carver G; Holmes K; Schleif WA; Danzeisen R; Hazuda D; Kessler J; Lineberger J; Miller MD; Emini EA
Bioorg Med Chem Lett; 2004 Feb; 14(4):947-52. PubMed ID: 15012999
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel (S)-alpha-phenyl-gamma-amino butanamide containing CCR5 antagonists via functionality inversion approach.
Zhang HS; Feng DZ; Chen L; Long YQ
Bioorg Med Chem Lett; 2010 Apr; 20(7):2219-23. PubMed ID: 20207141
[TBL] [Abstract][Full Text] [Related]
13. Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanes.
Finke PE; Oates B; Mills SG; MacCoss M; Malkowitz L; Springer MS; Gould SL; DeMartino JA; Carella A; Carver G; Holmes K; Danzeisen R; Hazuda D; Kessler J; Lineberger J; Miller M; Schleif WA; Emini EA
Bioorg Med Chem Lett; 2001 Sep; 11(18):2475-9. PubMed ID: 11549450
[TBL] [Abstract][Full Text] [Related]
14. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist.
Tagat JR; McCombie SW; Nazareno D; Labroli MA; Xiao Y; Steensma RW; Strizki JM; Baroudy BM; Cox K; Lachowicz J; Varty G; Watkins R
J Med Chem; 2004 May; 47(10):2405-8. PubMed ID: 15115380
[TBL] [Abstract][Full Text] [Related]
15. The design and discovery of novel amide CCR5 antagonists.
Pryde DC; Corless M; Fenwick DR; Mason HJ; Stammen BC; Stephenson PT; Ellis D; Bachelor D; Gordon D; Barber CG; Wood A; Middleton DS; Blakemore DC; Parsons GC; Eastwood R; Platts MY; Statham K; Paradowski KA; Burt C; Klute W
Bioorg Med Chem Lett; 2009 Feb; 19(4):1084-8. PubMed ID: 19167884
[TBL] [Abstract][Full Text] [Related]
16. 4,4-Disubstituted cyclohexylamine based CCR5 chemokine receptor antagonists as anti-HIV-1 agents.
Duan M; Aquino C; Dorsey GF; Ferris R; Kazmierski WM
Bioorg Med Chem Lett; 2009 Sep; 19(17):4988-92. PubMed ID: 19664920
[TBL] [Abstract][Full Text] [Related]
17. Syntheses and biological evaluation of 5-(piperidin-1-yl)-3-phenyl-pentylsulfones as CCR5 antagonists.
Shankaran K; Donnelly KL; Shah SK; Caldwell CG; Chen P; Finke PE; Oates B; MacCoss M; Mills SG; DeMartino JA; Gould SL; Malkowitz L; Siciliano SJ; Springer MS; Kwei G; Carella A; Carver G; Danzeisen R; Hazuda D; Holmes K; Kessler J; Lineberger J; Miller MD; Emini EA; Schleif WA
Bioorg Med Chem Lett; 2004 Jul; 14(13):3589-93. PubMed ID: 15177481
[TBL] [Abstract][Full Text] [Related]
18. Prospective CCR5 small molecule antagonist compound design using a combined mutagenesis/modeling approach.
Metz M; Bourque E; Labrecque J; Danthi SJ; Langille J; Harwig C; Yang W; Darkes MC; Lau G; Santucci Z; Bridger GJ; Schols D; Fricker SP; Skerlj RT
J Am Chem Soc; 2011 Oct; 133(41):16477-85. PubMed ID: 21942640
[TBL] [Abstract][Full Text] [Related]
19. Studies on the structure-activity relationship of 1,3,3,4-tetra-substituted pyrrolidine embodied CCR5 receptor antagonists. Part 2: Discovery of highly potent anti-HIV agents.
Li B; Jones ED; Zhou E; Chen L; Baylis DC; Yu S; Wang M; He X; Coates JA; Rhodes DI; Pei G; Deadman JJ; Xie X; Ma D
Bioorg Med Chem Lett; 2010 Sep; 20(17):5334-6. PubMed ID: 20674358
[TBL] [Abstract][Full Text] [Related]
20. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chains.
Shen DM; Shu M; Mills SG; Chapman KT; Malkowitz L; Springer MS; Gould SL; DeMartino JA; Siciliano SJ; Kwei GY; Carella A; Carver G; Holmes K; Schleif WA; Danzeisen R; Hazuda D; Kessler J; Lineberger J; Miller MD; Emini EA
Bioorg Med Chem Lett; 2004 Feb; 14(4):935-9. PubMed ID: 15012997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
